Dr. Gail Farfel is an accomplished life sciences executive and neuroscientist who previously served as Chief Development Officer at Zogenix Inc. and Marinus Pharmceuticals, where she directed development of fenfluramine and ganaxolone, respectively, for various rare pediatric genetic epilepsies. In addition to serving of the boards of Neurvati and GRIN Therapeutics, she also serves on the board of both the Dravet Syndrome Foundation and the American Society for Experimental Neurotherapeutics (ASENT). Dr. Farfel brings deep industry experience, having held executive and director roles at ProMIS Neurosciences Inc., Novartis Pharmaceuticals, AVROBio, DURECT Corporation and FAAH Pharma. With over 50 scientific publications and presentations in the fields of neuropsychopharmacology and drug effects, Dr. Farfel is a globally recognized thought leader in neuroscience research. She earned her bachelor’s degree in biochemistry from the University of Virginia and holds a PhD in neuropsychopharmacology from the University of Chicago, where she also serves as a Polsky Advisor in Life Sciences for the Polsky Center for Entrepreneurship and Innovation.